Navigation Links
Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results
Date:3/10/2017

SOUTH SAN FRANCISCO, Calif., March 10, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced that it will host a live conference call at 4:15 p.m. ET / 1:15 p.m. PT on Thursday, March 16, 2017 to discuss the company's financial results as of Dec. 31, 2016. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman. A summary of the fourth quarter and full year financial results and other highlights will be included in a press release to be issued prior to the call.

The live webcast of the call may be accessed by visiting http://www.titanpharm.com/news/events. The call can also be accessed by dialing 1-877-870-4263 (or 1-412-317-0790 from outside the U.S.) five minutes prior to the start time, and asking to be joined into the Titan Pharmaceuticals, Inc. call.

A replay of the call will be available approximately one hour after completion of the call by dialing 1-877-344-7529 and entering passcode 10103098. An audio recording of the call will also be archived on the Titan website.

About Titan Pharmaceuticals Titan Pharmaceuticals Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has granted commercial rights in the U.S. and Canada for Probuphine to Braeburn Pharmaceuticals. Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2016-financial-results-300421723.html


'/>"/>
SOURCE Titan Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. ISSYS Inc. will showcase its Titan Wireless Implantable Hemodynamic Monitor and its clinical study summary at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference (Booth 1638) in San Francisco (October 29 to 31, 2013)
2. Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System
3. Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction
4. Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
5. Smith & Nephew unveils its first 3D-printed titanium hip implant 1 March 2016
6. Olympus Has Fallen: False Claims Act Whistleblower Lawsuit Prompts Medical Device Titan To Strike A Record $623M Settlement, Kenney McCafferty Announces
7. Research and Markets - Global Urology Robotic Surgery Market Forecast to 2020 - Key Vendors are Intuitive Surgical, Titan Medical & TransEnterix
8. Titan Pharmaceuticals Appoints Two New Board Members
9. Titan Pharmaceuticals Receives FDA Communication On Ropinirole Implant Investigational New Drug Application
10. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
11. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2020)... SPRINGFIELD, Mass. (PRWEB) , ... February 14, 2020 ... ... of Science in Cannabis Science and Commerce beginning fall semester 2020, the first ... is designed for individuals interested in a career in the cannabis industry and ...
(Date:2/14/2020)... ... February 14, 2020 , ... ESO , ... and hospitals, today announced Dr. Daniel Kraft – Faculty Chair for Medicine at ... deliver one of three keynote presentations at Wave 2020 , ESO’s data, ...
(Date:2/14/2020)... ... February 14, 2020 , ... The Jim Ellis Automotive ... Atlanta (Children’s) raised through their annual Holiday Giving Campaign. The fundraiser has been ... vehicle sales between November 29, 2019, through January 2, 2020, are donated to ...
Breaking Medicine Technology:
(Date:2/21/2020)... , ... February 21, 2020 , ... Representatives with Bay-Bay Water today announced ... launch of Bay-Bay Water’s new company logo as part of the ongoing evolution of our ... at a time when the company is expanding its national reach. , “We have refreshed ...
(Date:2/21/2020)... ... February 21, 2020 , ... The American ... Cancer Leaders’ Summit in Boston, MA, in October 2021. The prestigious, invitation-only event—organized ... including prime ministers, ministers of health, city and industry leaders, senior executives and ...
(Date:2/20/2020)... , ... February 20, 2020 , ... R3 Stem Cell, ... was able to complete 70 complimentary stem cell procedures on military veterans ... therapies at no cost. , At the R3 Stem Cell Training Course for doctors ...
(Date:2/19/2020)... ... 19, 2020 , ... Spaulding Youth Center is thrilled to ... Flutie, Jr. Foundation for Autism. The grant will directly support Spaulding’s initiative to ... program will include the hiring of a fitness professional who will complete the ...
(Date:2/19/2020)... ... February 19, 2020 , ... Actor, director, and ... most known for his acting abilities demonstrated in blockbuster hits like the “John ... The Scenes” with Laurence Fishburne. “Behind The Scenes” features a broad array of ...
Breaking Medicine News(10 mins):